Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study to Evaluate the Efficacy and Safety of JNJ-268229 in Pediatric Subjects General Anesthetised

Next Previous
X
Search
Trial Profile

An Open-Label Study to Evaluate the Efficacy and Safety of JNJ-268229 in Pediatric Subjects General Anesthetised

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remifentanil (Primary)
  • Indications Intraoperative pain
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK

    • Most Recent Events

    • 26 Aug 2016 According to a Janssen Pharmaceutical Co. media release, remifentanil (Aruchiba) has been approved in Japan for additional indication of analgesia in the maintenance of general anesthesia in children based on results from this trial.
    • 02 Dec 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 08 Sep 2014 Planned End Date changed from 1 Nov 2015 to 1 Mar 2015, as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top